Shares of Shire PLC (NASDAQ:SHPG) gapped up prior to trading on Thursday . The stock had previously closed at $166.86, but opened at $171.50. Shire shares last traded at $178.13, with a volume of 4168095 shares changing hands.
Several research firms recently commented on SHPG. ValuEngine upgraded shares of Shire from a “sell” rating to a “hold” rating in a research report on Thursday. BidaskClub cut shares of Shire from a “buy” rating to a “hold” rating in a research note on Friday, November 30th. Zacks Investment Research reissued a “hold” rating on shares of Shire in a research note on Thursday, November 15th. B. Riley reissued a “buy” rating on shares of Shire in a research note on Tuesday. Finally, Berenberg Bank cut shares of Shire from a “buy” rating to a “hold” rating in a research note on Friday, September 7th. Nine research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Shire currently has an average rating of “Hold” and a consensus price target of $201.11.
The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.51 and a current ratio of 0.92. The company has a market capitalization of $54.14 billion, a price-to-earnings ratio of 11.40, a price-to-earnings-growth ratio of 1.60 and a beta of 1.01.
Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.65 by ($0.01). Shire had a return on equity of 12.70% and a net margin of 30.63%. The company had revenue of $3.87 billion for the quarter. During the same quarter in the previous year, the business posted $3.81 earnings per share. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Research analysts predict that Shire PLC will post 15.09 EPS for the current year.
Several large investors have recently bought and sold shares of the company. Legal & General Group Plc grew its stake in shares of Shire by 2.8% during the 2nd quarter. Legal & General Group Plc now owns 11,510 shares of the biopharmaceutical company’s stock worth $1,943,000 after purchasing an additional 317 shares during the period. Capital Bank & Trust Co grew its stake in shares of Shire by 42.7% during the 3rd quarter. Capital Bank & Trust Co now owns 1,070 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 320 shares during the period. Wetherby Asset Management Inc. grew its stake in shares of Shire by 5.9% during the 3rd quarter. Wetherby Asset Management Inc. now owns 6,080 shares of the biopharmaceutical company’s stock worth $1,102,000 after purchasing an additional 337 shares during the period. United Services Automobile Association grew its stake in shares of Shire by 2.2% during the 3rd quarter. United Services Automobile Association now owns 16,267 shares of the biopharmaceutical company’s stock worth $2,949,000 after purchasing an additional 354 shares during the period. Finally, Azimuth Capital Management LLC grew its stake in shares of Shire by 3.1% during the 2nd quarter. Azimuth Capital Management LLC now owns 12,044 shares of the biopharmaceutical company’s stock worth $2,033,000 after purchasing an additional 360 shares during the period. 20.49% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece was originally published by Equities Focus and is owned by of Equities Focus. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.equitiesfocus.com/2018/12/08/shire-shpg-shares-gap-up-to-171-50.html.
Shire Company Profile (NASDAQ:SHPG)
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Featured Story: Moving Average (MA)
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.